Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
Open Access
- 10 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (1), 247-257
- https://doi.org/10.1007/s13300-019-00742-8
Abstract
Introduction The effect of dipeptidyl peptidase-4 (DDP-4) inhibitors versus α-glucosidase inhibitors (AGIs) on the treatment of type 2 diabetes mellitus (T2DM) in a real-world setting is unknown. The aim of this real-world study was to compare the glucose-lowering effect and tolerability of vildagliptin as add-on to metformin monotherapy (VM) and AGI as add-on to metformin monotherapy (AM) in Chinese patients with T2DM. Methods This was a subgroup analysis of the China Prospective Diabetes Study, a post-marketing, prospective, observational, real-world study conducted at 52 centers in China. T2DM patients with inadequate glycemic control on metformin monotherapy who received VM or AM were included. The composite primary endpoint was glycemic control (hemoglobin A1c [HbA1c] < 7%) after 12 months in the absence of tolerability events (hypoglycemia, weight gain ≥ 3%, or gastrointestinal events leading to treatment discontinuation). Propensity score matching (PSM) was used to balance the two groups. Results The success rates of the composite endpoint were higher in the VM group (n = 604/159 before/after PSM) than in the AM group (n = 159/157 before/after PSM), but the difference was not statistically significant (before PSM: 53.0 vs. 46.5%, P = 0.148; after PSM: 56.7 vs. 45.9%, P = 0.055). The glycemic control rate and HbA1c reduction were similar between groups at 3, 6, and 12 months. Compared with the AM group, the VM group had lower risks of any tolerability event (relative risk [RR] 0.53, 95% confidence interval [CI] 0.33–0.83, P = 0.006), of any adverse event (AE) (RR 0.64, 95% CI 0.41–1.00, P = 0.049), and of any serious AE (RR 0.45, 95% CI 0.25–0.81, P = 0.007). Conclusion The results of this real-world study suggest that vildagliptin as add-on to metformin monotherapy had a similar glucose-lowering effect to AGI as add-on to metformin monotherapy, but with better safety.Funding Information
- This study and the article's preparation fees, processing charges and open access fees were funded by Novartis.
This publication has 27 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2018 Abridged for Primary Care ProvidersClinical Diabetes, 2018
- Standards of care for type 2 diabetes in ChinaDiabetes/Metabolism Research and Reviews, 2016
- Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitusDiabetes Research and Clinical Practice, 2016
- The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2015
- Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响:一项meta分析Journal of Diabetes, 2014
- Efficacy of acarbose in different geographical regions of the world: analysis of a real‐life databaseDiabetes/Metabolism Research and Reviews, 2014
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.2010
- Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12‐week, randomized, double‐blind, active‐controlled studyDiabetes, Obesity and Metabolism, 2010
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trialDiabetic Medicine, 2008
- α-Glucosidase Inhibitors for Patients With Type 2 DiabetesDiabetes Care, 2005